Sept. 29, 2017—Beckman Coulter Life Sciences introduced its DuraClone RE antibody panels for the detection of rare, abnormal events in blood disorders. The panels provide tools to study low frequency populations of either abnormal CD5+ B cells (RE CLB), abnormal plasma cells (RE PC), or abnormal B progenitor cells (RE ALB).
The three standardized, preformulated DuraClone RE kits, for research use only, deliver high sensitivity for rare cell populations and are able to accommodate either large sample volumes or high cellular concentrations. Using dry, unitized antibody combinations helps preserve the strict assay conditions essential for reliable, reproducible rare event analysis.
The panels aim to eliminate errors from manual antibody pipetting, streamline workflow, improve turnaround time, and simplify inventory management. The kits are stable at room temperature, even when opened, and are easy to transfer between laboratories. The panels are available in a 25-test package with three complete compensation kits specific for each panel.
“Beckman Coulter is recognized for the quality of its reagents, and we recognize that preserving strict assay conditions is integral to rare event analysis. This has led to the development of our next-generation DuraClone RE kits, produced in collaboration with experts from leading clinical research laboratories. They told us that streamlined workflow and standardization of results were essential to the experimental robustness of their longitudinal and multicentric research into blood disorders,” Mario Koksch, vice president and general manager of Beckman Coulter’s Cytometry Business Unit, said in a statement.